Drug Trial Radar · NCT05259839
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
283
Actual
Start
Oct 20, 2022
Primary completion
Sep 2033
Study completion Sep 2033
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
EtentamigDrug
Intravenous (IV) Infusion
DexamethasoneDrug
Oral; Tablet or IV Infusion
LenalidomideDrug
Oral; Capsule
PomalidomideDrug
Oral; Capsule
DaratumumabDrug
Subcutaneous Injection (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicities (DLT) of EtentamigTime frame: Up to approximately 28 Days
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 3 Years
Locations
49 sites in 7 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences /ID# 243096
Little Rock, Arkansas
Sylvester Comprehensive Cancer Center /ID# 243673
Miami, Florida
Moffitt Cancer Center /ID# 243437
Tampa, Florida
University of Maryland, Baltimore /ID# 243679
Baltimore, Maryland
Dana-Farber Cancer Institute /ID# 249529
Boston, Massachusetts
University of Massachusetts - Worcester /ID# 243977
Worcester, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438
Ann Arbor, Michigan
The Valley Hospital /ID# 243829
Paramus, New Jersey
Rutenberg Cancer Center /ID# 244647
New York, New York
Memorial Sloan Kettering Cancer Center /ID# 244656
New York, New York
Atrium Health Levine Cancer Institute /ID# 242851
Charlotte, North Carolina
University of Texas - Southwestern Medical Center /ID# 243273
Dallas, Texas
Huntsman Cancer Institute /ID# 242872
Salt Lake City, Utah
University of Washington /ID# 243172
Seattle, Washington
Froedtert Memorial Lutheran Hospital /ID# 242654
Milwaukee, Wisconsin
St George Hospital - Kogarah /ID# 243740
Kogarah, New South Wales, Australia
Calvary Mater Newcastle /ID# 243730
Waratah, New South Wales, Australia
Monash Health - Monash Medical Centre - Clayton /ID# 244403
Clayton, Victoria, Australia
St Vincent's Hospital Melbourne /ID# 256879
Fitzroy Melbourne, Victoria, Australia
Peter MacCallum Cancer Ctr /ID# 256880
Melbourne, Victoria, Australia
Epworth Healthcare /ID# 243734
Richmond, Victoria, Australia
Fiona Stanley Hospital /ID# 244753
Murdoch, Western Australia, Australia
Universitaetsklinikum Essen /ID# 242819
Essen, Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 243141
Hamburg, Germany
Universitaetsklinikum Tuebingen /ID# 242815
Tübingen, Baden-Wurttemberg, Germany
Universitaetsklinikum Regensburg /ID# 242837
Regensburg, Bavaria, Germany
Universitaetsklinikum Wuerzburg /ID# 242826
Würzburg, Bavaria, Germany
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 242581
Bologna, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 244057
Milan, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 242584
Meldola, Forlì-Cesena, Italy
IRCCS Ospedale San Raffaele /ID# 242583
Milan, Milano, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 242582
Rome, Roma, Italy
Nagoya City University Hospital /ID# 249094
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East /ID# 245889
Kashiwa-shi, Chiba, Japan
Hokkaido University Hospital /ID# 245966
Sapporo, Hokkaido, Japan
Kanazawa University Hospital /ID# 246812
Kanazawa, Ishikawa-ken, Japan
Okayama Medical Center /ID# 245882
Okayama, Okayama-ken, Japan
Yamagata University Hospital /ID# 245888
Yamagata, Yamagata, Japan
Szpital Wojewodzki w Opolu sp. z o.o. /ID# 243954
Opole, Lower Silesian Voivodeship, Poland
Uniwersytecki Szpital Kliniczny We Wroclawiu /ID# 243246
Wroclaw, Lower Silesian Voivodeship, Poland
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.